We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (ADAMANT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02579252
Recruitment Status : Completed
First Posted : October 19, 2015
Last Update Posted : November 14, 2019
Information provided by (Responsible Party):
Axon Neuroscience SE

Brief Summary:

This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with mild Alzheimer's disease.

60% of participants will receive AADvac1 and 40% of participants will receive placebo.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Biological: AADvac1 Drug: Placebo Phase 2

Detailed Description:

Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder of the brain. Over the course of the disease, pathological proteins accumulate in the brain, damaging neurons, thus causing them to lose their connections and die.

Currently available treatments are designed to compensate for the neurotransmitter loss caused by the disease without affecting the disease process itself.

AADvac1 is designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology in AD). These antibodies are expected to prevent tau protein from aggregating, to facilitate the removal of tau protein aggregates and prevent the spreading of pathology, slowing or halting the progress of the disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 208 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease
Study Start Date : March 2016
Actual Primary Completion Date : June 2019
Actual Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AADvac1

AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.

Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.

Biological: AADvac1
Placebo Comparator: Placebo
Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.
Drug: Placebo

Primary Outcome Measures :
  1. Safety (all-case treatment-emergent adverse events except local reactions) [ Time Frame: 24 months ]
    The safety and tolerability of AADvac1 in the treatment of patients with mild Alzheimer disease, as assessed by AEs, vital signs, ECG, laboratory measures, MRI of the brain, physical and neurological examination, Columbia Suicide Severity Rating Scale (C-SSRS) and review of the Patient Diary

Secondary Outcome Measures :
  1. Clinical Dementia Rating (CDR) Sum of Boxes [ Time Frame: 24 months ]
    The domain scores of the standard 6-domain CDR assessment will be summed up to obtain a Sum-of-Boxes score of 0-18

  2. Custom cognitive battery (composite standard score) [ Time Frame: 24 months ]

    A composite standard score will be calculated from the following tests:

    Cogstate International Shopping List Task (memory)

    • immediate free recall
    • delayed free recall
    • delayed recognition

    Cogstate One Card Learning Task (memory)

    Cogstate One Card Back Task (memory)

    Category Fluency Test (executive function, language)

    Letter Fluency Test (executive function, language)

    Digit Symbol Coding (executive functioning, working memory and processing speed)

  3. Alzheimer's Disease Cooperative Study - Activities of Daily Living questionnaire (version for Mild Cognitive Impairment) (ADCS MCI ADL) [ Time Frame: 24 months ]
    Activities of daily living will be assessed using the informant-based ADCS questionnaire (both the score for the 18-point and the 24-point version will be calculated)

  4. Immunogenicity [ Time Frame: 24 months ]

Other Outcome Measures:
  1. Exploratory: Fludeoxyglucose Positron Emission Tomography (FDG PET) assessment of brain metabolism (change in cerebral glucose metabolic rate expressed as Standardised Uptake Value Ratio [SUVR] change, multiple regions of interest) [ Time Frame: 24 months ]
  2. Exploratory: MRI volumetry [ Time Frame: 24 months ]
  3. Exploratory: Cerebrospinal fluid (CSF) biomarkers [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria (abbreviated):

  • Diagnosis of probable Alzheimer's disease according to the revised National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (McKhann 2011).
  • Mini Mental State Examination (MMSE) score ≥ 20 and ≤ 26.
  • Brain MRI finding consistent with the diagnosis of Alzheimer's disease
  • Medial temporal lobe atrophy: Scheltens score of ≥ 2 (on a scale of 0-4 on the more atrophied side) AND/OR positive AD biomarker profile in the CSF (amyloid+, tau+)
  • At least 6 years of formal elementary education.
  • Age 50-85 years.
  • Fluency in the local language and sufficient auditory and visual capacities to allow neuropsychological testing.
  • Ability to read and understand the informed consent.
  • Stable therapy with an acetylcholinesterase inhibitor for at least 3 months prior to screening.
  • If the patient is on memantine treatment, the dose regimen must be stable for at least 3 months prior to screening.
  • Hachinski Ischemia Scale score ≤ 4.
  • Availability of a caregiver.
  • Female patients must be either surgically sterile or at least 2 years postmenopausal.
  • Male patients must either be surgically sterile, or he and his female spouse/partner who is of childbearing potential must be using highly effective contraception starting at screening and continuing throughout the study period.
  • Patient provides written informed consent.

Exclusion criteria (abbreviated):

  • Participation in another clinical study within 3 months prior to screening.
  • Pregnant or breastfeeding female.
  • Not expected to complete the clinical study.
  • Known allergy to components of the vaccine.
  • Contraindication for MRI imaging.
  • Any of the following detected by brain MRI:

    • Infarction in the territory of large vessels
    • More than one lacunar infarct.
    • Any lacunar infarct in a strategically important location.
    • Confluent hemispheric deep white matter lesions (Fazekas grade 3).
    • Other focal lesions which may be responsible for the cognitive status of the patient or any other abnormalities associated with significant central nervous disease other than Alzheimer's disease.
  • Surgery (under general anaesthesia) within 3 months prior to screening and/or scheduled surgery (under general anaesthesia) during the whole study period.
  • Patient has a history and/or currently suffers from a clinically significant autoimmune disease, or is expected to receive immunosuppressive or immunomodulatory treatment at the present or in the future.
  • Recent history of cancer (last specific treatment ≤ 5 years prior to Screening).
  • Myocardial infarction within 2 years prior to screening.
  • Hepatitis B, C, HIV or Syphilis.
  • Active infectious disease.
  • Presence and/or history of immunodeficiency.
  • Patient currently suffering from a clinically important systemic illness:

    • poorly controlled congestive heart failure (NYHA ≥ 3)
    • BMI > 40
    • poorly controlled diabetes (HbA1c > 7.5%)
    • severe renal insufficiency (eGFR < 30 mL/min)
    • chronic liver disease - ALT (alanine aminotransferase) > 66 U/L in females or > 80 U/L in males, AST (aspartate aminotransferase) > 82 U/L
    • QTc interval prolongation in ECG (> 450 ms)
    • other clinically significant systemic illness, if considered relevant by the investigator
  • Hypothyroidism, defined as TSH (thyroid-stimulating hormone) elevation > 5.000 mcIU/mL, and/or FT4 levels < 0.7 ng/dL. Patients with corrected hypothyroidism are eligible for the study provided that treatment has been stable for 3 months before study entry.
  • Valid diagnosis of a significant psychiatric illness such as schizophrenia, any type of psychotic disorder or bipolar affective disorder.
  • Current depressive episode (Geriatric Depression Scale GDS ≥ 6) or major depressive episode within the last 1 years.
  • Metabolic or toxic encephalopathy or dementia due to a general medical condition.
  • History of alcohol or drug abuse or dependence within the past 2 years.
  • Wernicke's encephalopathy.
  • History or evidence of any CNS disorder other than AD that could be the cause of dementia.
  • Cerebrovascular disease (ischemic or haemorrhagic stroke), or diagnosis of possible, probable or definite vascular dementia.
  • Epilepsy.
  • Treatment with experimental immunotherapeutics including intravenous immunoglobulin within 3 months prior to screening.
  • Treatment with experimental therapies for AD aiming at disease-modification within 3 months prior to screening.
  • Patient is currently being treated or was treated in the past with any active vaccines for AD.
  • Treatment with immunosuppressive drugs.
  • Change in dose of previous and current medications within the last 30 days prior to Screening (V01), if considered clinically relevant by the investigator.
  • Vitamin B12 deficiency (serum vitamin B12 < 191 pg/mL).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02579252

Show Show 42 study locations
Sponsors and Collaborators
Axon Neuroscience SE
Layout table for investigator information
Principal Investigator: Reinhold Schmidt, Prof. MD. Medical University, Graz, Austria
Layout table for additonal information
Responsible Party: Axon Neuroscience SE
ClinicalTrials.gov Identifier: NCT02579252    
Other Study ID Numbers: AC-AD-003
2015-000630-30 ( EudraCT Number )
First Posted: October 19, 2015    Key Record Dates
Last Update Posted: November 14, 2019
Last Verified: November 2019
Keywords provided by Axon Neuroscience SE:
tau protein
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders